Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 6/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829921 | 1.00 | POLB (0.51) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3831328 | 0.90 | HSD17B10 (0.59) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3831329 | 0.90 | HSD17B10 (0.59) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3832394 | 0.89 | MEN1 (0.52) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3832389 | 0.89 | MEN1 (0.52) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3826091 | 0.87 | GAA (0.66) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3826090 | 0.87 | GAA (0.66) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3828037 | 0.87 | HSD17B10 (0.51) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3828033 | 0.87 | HSD17B10 (0.51) | POLBRAB9AGAAHSD17B10FFAR2 | |
| SCHEMBL3225960 | 0.84 | HSD17B10 (0.51) | POLBRAB9AGAAHSD17B10FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099778-A2 | AMIDO ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080181866-A1 | Amido Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008064218-A2 | AMIDO ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181866-A1 | Amido Anti-viral Compounds | ZC3HAV1, U2SURP, ZC3HAV1L | POLB 1374/4885RAB9A 702/4885GAA 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.